- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05953038
Occupation par le LSD du récepteur de la sérotonine 2A dans le cerveau humain (dOccLS)
Acide lysergique diéthylamide Occupation du récepteur de la sérotonine 2A dans le cerveau humain
The investigators wish to quantify the relation between administered dose of lysergic acid diethylamide (LSD), plasma LSD levels, and occupancy at the serotonin 2A receptor (5-HT2AR) using [11C]CIMBI-36 positron emission tomography.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Healthy participants will be administered one of a single dose of lysergic acid diethylamide (LSD) between 25 and 200 micrograms equivalent freebase. They will receive [11C]CIMBI-36 positron emission tomography (PET) scans at baseline and twice following LSD administration during peak and declining drug effects. PET scans will be acquired in a simultaneous PET/Magnetic Resonance Imaging (MRI) scanner which will also collect functional brain imaging data. Venous blood samples will be repeatedly drawn during acute drug effects for quantification of plasma LSD levels. Participants will also repeatedly rate their subjective drug intensity on a scale from 0 to 10 during acute drug effects. Together these data will inform the dose-binding relation of LSD at the serotonin (5-HT) 2A receptor, the primary site of action. This data will also inform the relation between 5-HT2A receptor binding by LSD and the induced subjective effects, as well as the effects on functional brain activity as measured with functional MRI.
Type d'étude
Inscription (Estimé)
Phase
- Première phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Gitte M Knudsen, DMsc, MD
- Numéro de téléphone: +45 35456720
- E-mail: gmk@nru.dk
Sauvegarde des contacts de l'étude
- Nom: Patrick M Fisher, PhD
- Numéro de téléphone: +45 35456714
- E-mail: patrick.fisher@nru.dk
Lieux d'étude
-
-
-
Copenhagen, Danemark, 2100
- Recrutement
- Neurobiology Research Unit, Rigshospitalet
-
Contact:
- Gitte M Knudsen, DMSc
- Numéro de téléphone: +45 35456720
- E-mail: gmk@nru.dk
-
Sous-enquêteur:
- Drummond E. McCulloch, BSc
-
Sous-enquêteur:
- Patrick M. Fisher, PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
• Healthy individual between 18-75 years old
Exclusion Criteria:
- Current or past history of primary psychiatric illness (The Diagnostic and Statistical Manual of Mental Disorders IV axis-I or World Health Organisation International Classification of Diseases-10 diagnostic classification)
- Current or past history of primary psychiatric illness (The Diagnostic and Statistical Manual of Mental Disorders IV axis-I or World Health Organisation International Classification of Diseases-10 diagnostic classification) in a first degree relative (i.e., parents, siblings)
- Current or past history of neurological disease, significant somatic condition/disease
- Use of medication that could potentially influence results (e.g.., drugs that act on relevant components of the serotonin system or may interfere with metabolism of study drug)
- Non-fluent Danish language skills
- Profound visual or auditory impairments
- Severe learning disability
- Pregnancy on the scan date, verified by a pregnancy test (test omitted if confirmed that individual is post-menopausal)
- Lactation (females)
- Contraindications for magnetic resonance imaging (e.g., pacemaker, claustrophobia, etc.)
- Contraindications for positron emission tomography
- Alcohol or drug abuse
- Allergy to administered compounds
- Participant in research study with >10 millisievert exposure within the past year or significant occupational exposure to radioactive substances
- Abnormal ECG (ECG indicating current or previous heart disease or predisposition to heart disease, e.g., QT prolongation) or use of QT prolonging medication
- Use of psychedelic substance within the preceding six months
- Blood donation up to three months before the study (i.e., more than 500ml of blood)
- Head injury or concussion resulting in loss of consciousness for more than 2 min
- Haemoglobin levels < 7.8 mmol/l for women and 8.4 mmol/l for men
- Ferritin levels outside normal range (12-300 µg/L)
- Body-weight < 50 kg or > 110kg
- body-mass index > 35
- Individual assessment by research staff deeming drug administration unsafe due to ethical or psychological circumstance of the participant
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: LSD dose-ranging group
All participants will receive between 25 and 200 micrograms of lysergic acid diethylamide equivalent as freebase, single blinded with respect to dose. Simultaneous PET/MR imaging will be performed during acute drug effects. |
D-Lysergic Acid Diethylamide (LSD) D-tartrate as oral drinking solution (water / ethanol 20% m/m)
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Plasma LSD - serotonin 2A receptor (5-HT2AR) occupancy relation
Délai: Within 24 hours following drug administration
|
Occupancy will be estimated by comparing non-displaceable binding potential (BPND) values using baseline and intervention rescans as calculated using a simplified reference tissue model (SRTM). Occupancy values will be compared to plasma lysergic acid diethylamide (LSD) levels. |
Within 24 hours following drug administration
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Subjective drug intensity - 5-HT2AR occupancy relation
Délai: Within 24 hours following drug administration
|
Occupancy will be calculated as described above. Subjective drug intensity is collected during positron emission tomography (PET) scans by asking participants. |
Within 24 hours following drug administration
|
|
fMRI network disintegration - 5-HT2AR occupancy relation
Délai: Within 24 hours following drug administration
|
functional magnetic resonance imaging (fMRI) data will be used to estimate functional-network connectivity using a standard functional brain atlas. Then the relation between decreases in functional network connectivity and 5-HT2AR occupancy will be estimated. |
Within 24 hours following drug administration
|
|
fMRI brain entropy - 5-HT2AR occupancy relation
Délai: Within 24 hours following drug administration
|
fMRI brain entropy will be estimated by the shannon entropy of dynamic conditional correlation of within and between network connectivity as well as the lempel-ziv complexity of concatenated binarised blood-oxygen level dependent (BOLD) signals across regions. The relation between each of these measures with 5-HT2AR occupancy will be estimated. |
Within 24 hours following drug administration
|
|
Cerebral perfusion - 5-HT2AR occupancy relation
Délai: Within 24 hours following drug administration
|
Cerebral perfusion will be estimated using arterial spin labelling. The relation between this measure and 5-HT2AR occupancy will be estimated. |
Within 24 hours following drug administration
|
|
Administered LSD dose - 5-HT2AR occupancy relation
Délai: Within 24 hours following drug administration
|
Administered dose (25 to 200 mcg) will be compared with peak LSD occupancy to determine what doses produce maximal occupancy at the 5-HT2AR. |
Within 24 hours following drug administration
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Hysteresis effect of 5-HT2AR binding
Délai: Within 24 hours following drug administration
|
Estimated dose-occupancy curves derived from the first PET scan and second PET scan will be calculated separately to evaluate whether there are differences in estimated plasma level-occupancy relation at different timepoints following LSD administration which may indicate a hysteresis effect due to peripheral LSD metabolism without unbinding of LSD from the 5-HT2A receptor. |
Within 24 hours following drug administration
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Gitte M Knudsen, DMsc, MD, Copenhagen University Hospital, Rigshospitalet
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- H-21060056
- 2021-002633-42 (Numéro EudraCT)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .